" class="no-js "lang="en-US"> TheraVet - Medtech Alert
Saturday, September 13, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
TheraVet | Pharmtech Focus

TheraVet

About TheraVet

TheraVet

TheraVet: Innovative treatments for osteoarticular diseases in small companion animals TheraVet is a start-up company created in November 2017 based at Biopark Charleroi Brussels South (Gosselies, Belgium), specialized in the treatment of osteo-articular diseases in small companion animals such as dogs using a portfolio of biological and synthetic products covering selected orthopaedics indications with unmet medical needs.

Related Story

News

 TheraVet Signs an International Distribution Agreement for BIOCERA-VET Covering 24 Countries | MTA

TheraVet Signs an International Distribution Agreement for BIOCERA-VET Covering 24 Countries

February 21 2023

TheraVet, a pioneering company in the management of osteoarticular diseases in pets, announces the signing […]

Industry News

 TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis | PTF

TheraVet Optimizes its Commercial Strategy in France with a New Distribution Agreement with Elvetis

December 12 2022

TheraVet, a pioneering biotechnology company in the treatment of bone and joint diseases in pets, […]

Diseases

 TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor

TheraVet Signs an Important Distribution Agreement With the Orthopaedics & Surgical Instrumentation Distributor, Veterinary Instrumentation

May 10 2022

TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases […]